Head-to-head evidence
albuterol HFA (Proventil HFA) vs albuterol (Ventolin)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol HFA (Proventil HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
In this trial, Proventil-HFA is the established reference product that the investigational Armstrong's albuterol-HFA is being compared against, rather than the agent under primary evaluation itself, and no results have been posted yet.
albuterol (Ventolin)
Developed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT06676319 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol HFA (Proventil HFA)'s landscape · albuterol (Ventolin)'s landscape